BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rare natural history study of patients living with inherited retinal diseases [Yahoo! Finan...
BAYER AG S/ADR (BAYRY)
NASDAQ:AMEX Investor Relations:
investor.bayer.com
Company Research
Source: Yahoo! Finance
inform the future clinical trial design for BlueRock's pipeline of cell therapies for treating blindness CAMBRIDGE, MA USA and COLUMBIA, MD, March 25, 2024 (GLOBE NEWSWIRE) -- BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG, and Foundation Fighting Blindness today announced a collaboration to add a new cohort to the Foundation's Uni-Rare natural history study of people living with inherited retinal diseases (IRDs) caused by rare single gene mutations. The new cohort will include patients living with IRDs caused by mutations in multiple genes. BlueRock plans to use the data generated by the Uni-Rare study to support the identification and development of sensitive, reliable outcome measures for clinical trials and to enable the discovery and development of new therapies for treating IRDs. “BlueRock is developing a pipeline of cell therapies that we believe has great potential for restoring vision in peopl
Show less
Read more
Impact Snapshot
Event Time:
BAYRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BAYRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BAYRY alerts
High impacting BAYER AG S/ADR news events
Weekly update
A roundup of the hottest topics
BAYRY
News
- Vividion Therapeutics and Roche Jointly Publish Landmark Nature Paper on Clinical-Stage Covalent Allosteric Inhibitor of Werner Helicase (WRN) [Yahoo! Finance]Yahoo! Finance
- Seed Paper Bags Bloom as Eco-Conscious Consumers Drive Market to $213.2 Million by 2034 | Future Market Insights, Inc. [Yahoo! Finance]Yahoo! Finance
- Missouri House backs legal shield for weedkiller maker facing thousands of cancer-related lawsuits [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Missouri House backs legal shield for weedkiller maker facing thousands of cancer-related lawsuits [Yahoo! Finance]Yahoo! Finance
- Judge slashes $857 mln Monsanto verdict to $438 mln in PCBs case [Reuters]Reuters